

## Erratum to: Percutaneous transfemoral transcatheter mitral valve replacement of a degenerated mitral bioprosthesis: initial experience in Southeast Asia with nine-month follow-up

Chiam PT, Lim YT, Lim CP, Sivathasan C

*Singapore Med J* 2020; 61(8): 445-446; <https://doi.org/10.11622/smedj.2020019>

The last paragraph of the article should read:

“This case demonstrates that the percutaneous transfemoral (transvenous) route for transcatheter mitral valve-in-valve replacement is feasible, leading to a successful procedure, a short hospital stay, preservation of renal function and a good clinical outcome at nine months.”

The following sentences were erroneously included in the final paragraph of the article:

*“Mitral valvuloplasty or mitral valve replacement is indicated for symptomatic patients with severe or very severe MS. In patients with progressive MS and symptoms without other cause, mitral valvuloplasty can be considered.”*

<https://doi.org/10.11622/smedj.2020136>